Methods for treatment of rheumatoid arthritis and accelerated atherosclerosis with an anti-Apo B100 antibody
AssigneeAbcentra, LLC
InventorsBertrand C. Liang, Stacey Ruiz, Christopher John Farina
Life of this patent
Estimating the term…
Abstract
Compositions and methods for treating rheumatoid arthritis and/or accelerated atherosclerosis are provided, including an inhibitor of oxidized or malondialdehyde-modified low density lipoprotein (LDL) for administration to a subject. Exemplary inhibitors of oxidized LDL include an anti-oxidized LDL antibody, which results in a reduction in the secretion of pro-inflammatory cytokine from primary monocyte in vitro and the plasma cytokine level of inflammatory cytokine in vivo.
Claims18
A method for treating, reducing the severity of, slowing progression of, or inhibiting rheumatoid arthritis in a subject in need thereof, comprising:
- administering to the subject an effective amount of an antibody or antibody fragment
- an HCDR 1 (HCDR1) having the sequence of SEQ ID NO:
- 2, an HCDR 2 (HCDR2) having the sequence of SEQ ID NO:
- 3, and an HCDR 3 (HCDR3) having the sequence of SEQ ID NO:
- 4, and an LCDR 1 (LCDR1) having a sequence of SEQ ID NO:
- 5, an LCDR 2 (LCDR2) having a sequence of SEQ ID NO:
- 6, and an LCDR 3 (LCDR3) having a sequence of SEQ ID NO:
- 7.
A method of reducing the severity of or the likelihood of developing inflammation in a subject, comprising:
- administering to the subject an effective amount of an antibody or antibody fragment wherein the antibody comprises an HCDR 1 (HCDR1) having the sequence of SEQ ID NO:
- 2, an HCDR 2 (HCDR2) having the sequence of SEQ ID NO:
- 3, and an HCDR 3 (HCDR3) Having the sequence of SEQ ID NO:
- 4, and an LCDR 1 (LCDR1) having a sequence of SEQ ID NO:
- 5, an LCDR 2 (LCDR2) having a sequence of SEQ ID NO:
- 6, and an LCDR 3 (LCDR3) having a sequence of SEQ ID NO:
- 7, wherein the subject shows symptoms of rheumatoid arthritis or has been diagnosed with rheumatoid arthritis.
Dependencies are inferred from the claim text.